Aytu Biopharma (AYTU) Asset Writedowns and Impairment (2020 - 2026)
Aytu Biopharma (AYTU) posted quarterly Asset Writedowns and Impairment of $700000.0 for Q1 2026, up 600.0% year-over-year from $100000.0 in Q1 2025, and down 12.5% quarter-over-quarter from $800000.0 in Q4 2025.
Aytu Biopharma (AYTU) Asset Writedowns and Impairment (2020 - 2026) Analysis & Trends
Aytu Biopharma (AYTU) has reported Asset Writedowns and Impairment for 7 consecutive years, with $700000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Asset Writedowns and Impairment rose 600.0% year-over-year to $700000.0; the TTM figure through Mar 2026 stood at $1.9 million (up 40.24% YoY), while the FY2025 annual figure was $325000.0, down 72.67% from the prior year.
- Asset Writedowns and Impairment retreated to $700000.0 in Q1 2026 per AYTU's latest filing, from $800000.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $45.2 million in Q1 2022 and bottomed at -$62.5 million in Q2 2022.
- Historically, Asset Writedowns and Impairment has averaged -$551562.5 across 5 years, with a median of $112500.0 in 2023.
- On a YoY basis, Asset Writedowns and Impairment climbed as much as 2500.0% in 2022 and fell as far as 1598.29% in 2022.
- Aytu Biopharma's Asset Writedowns and Impairment stood at $2.6 million in 2022, then sank by 96.15% to $100000.0 in 2023, then changed by 0.0% to $100000.0 in 2024, then jumped by 700.0% to $800000.0 in 2025, then retreated by 12.5% to $700000.0 in 2026.
- Business Quant data shows AYTU's Asset Writedowns and Impairment at $700000.0 in Q1 2026, $800000.0 in Q4 2025, and $278000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - |
| 10 | Aytu Biopharma | 24.70 Mn | -2.01 Mn | 7.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 700,000.00 |
| Mar 31, 2026 | 700,000.00 |
| Dec 31, 2025 | 800,000.00 |
| Dec 31, 2025 | 800,000.00 |
| Sep 30, 2025 | 278,000.00 |
| Sep 30, 2025 | 278,000.00 |
| Jun 30, 2025 | 125,000.00 |
| Jun 30, 2025 | 125,000.00 |
| Mar 31, 2025 | 100,000.00 |
| Mar 31, 2025 | 100,000.00 |
| Dec 31, 2024 | 100,000.00 |
| Dec 31, 2024 | 100,000.00 |
| Sep 30, 2024 | 68,000.00 |
| Sep 30, 2024 | 68,000.00 |
| Jun 30, 2024 | 1.09 Mn |
| Jun 30, 2024 | 1.09 Mn |
| Mar 31, 2024 | 100,000.00 |
| Mar 31, 2024 | 100,000.00 |
| Dec 31, 2023 | 100,000.00 |
| Dec 31, 2023 | 100,000.00 |